Tags

Type your tag names separated by a space and hit enter

Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways.
Int J Oncol 2016; 48(6):2508-20IJ

Abstract

RSK2 (90 kDa ribosomal S6 kinase) is a downstream effector of the Ras/ERK (extracellular signal-regulated kinase) signaling pathway that has major functions in cell biological activities, including regulating nuclear signaling, cell cycle progression, cell proliferation, cell growth, protein synthesis, cell migration and cell survival, and is expressed in most types of human malignant tumors, including lung cancer, prostate and breast tumors, skin cancer and osteosarcomas (OS). RSK2 was found to be essential for osteosarcoma formation. To investigate whether RSK2 is expressed at high levels in human osteosarcome tissues and whether its expression is correlated with the aggressive biological behavior of osteosarcoma cell line (OCLs), we assessed the association between RSK2 expression and OS cell progression, as well as the effects of RSK2 inhibition on the biological activities of osteosarcoma cells. We performed immunohistochemistry to analyze the expression of RSK2 in specimens from 30 humans with osteosarcoma, and 15 normal tissues. RSK2 gene expression levels in 30 specimens with osteosarcoma were significantly higher than those of normal tissues. We performed RNA interference on three OCLs to evaluate cell apoptosis, cell growth, cell proliferation, cell motility, chemosensitivity and oncogenicity. After transfection with RSK2 shRNA, increased cell apoptosis, cell growth inhibition, cell cycle progression, weaker cell proliferation, cell migration and weaker tumor formation were observed in all OCLs. These results suggested that RSK2 expression may mediate the biological activities of OS cells and RSK2 may be an effective therapeutic target for the treatment of osteosarcomas. The AKT/mTOR, MAPK/ERK/c-Fos and Bcl2/Bax pathways were analysed to clarify the mechanisms involved.

Authors+Show Affiliations

Department of Orthopaedic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China.Department of Clinical Laboratory, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330008, P.R. China.Department of Orthopaedic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China.Department of Orthopaedic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China.Department of Orthopaedic Surgery, The Second Affiliated Hospital of Neimenggu Medical University, Huhehaote, Neimeng 010030, P.R. China.Department of Orthopaedic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China.Department of Orthopaedic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China.Department of Orthopaedic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27082640

Citation

Qiu, Quanhe, et al. "Downregulation of RSK2 Influences the Biological Activities of Human Osteosarcoma Cells Through Inactivating AKT/mTOR Signaling Pathways." International Journal of Oncology, vol. 48, no. 6, 2016, pp. 2508-20.
Qiu Q, Jiang J, Lin L, et al. Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways. Int J Oncol. 2016;48(6):2508-20.
Qiu, Q., Jiang, J., Lin, L., Cheng, S., Xin, D., Jiang, W., ... Hu, Z. (2016). Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways. International Journal of Oncology, 48(6), pp. 2508-20. doi:10.3892/ijo.2016.3481.
Qiu Q, et al. Downregulation of RSK2 Influences the Biological Activities of Human Osteosarcoma Cells Through Inactivating AKT/mTOR Signaling Pathways. Int J Oncol. 2016;48(6):2508-20. PubMed PMID: 27082640.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways. AU - Qiu,Quanhe, AU - Jiang,Jing, AU - Lin,Liangbo, AU - Cheng,Si, AU - Xin,Daqi, AU - Jiang,Wei, AU - Shen,Jieliang, AU - Hu,Zhenming, Y1 - 2016/04/08/ PY - 2016/01/17/received PY - 2016/02/18/accepted PY - 2016/4/16/entrez PY - 2016/4/16/pubmed PY - 2017/3/11/medline SP - 2508 EP - 20 JF - International journal of oncology JO - Int. J. Oncol. VL - 48 IS - 6 N2 - RSK2 (90 kDa ribosomal S6 kinase) is a downstream effector of the Ras/ERK (extracellular signal-regulated kinase) signaling pathway that has major functions in cell biological activities, including regulating nuclear signaling, cell cycle progression, cell proliferation, cell growth, protein synthesis, cell migration and cell survival, and is expressed in most types of human malignant tumors, including lung cancer, prostate and breast tumors, skin cancer and osteosarcomas (OS). RSK2 was found to be essential for osteosarcoma formation. To investigate whether RSK2 is expressed at high levels in human osteosarcome tissues and whether its expression is correlated with the aggressive biological behavior of osteosarcoma cell line (OCLs), we assessed the association between RSK2 expression and OS cell progression, as well as the effects of RSK2 inhibition on the biological activities of osteosarcoma cells. We performed immunohistochemistry to analyze the expression of RSK2 in specimens from 30 humans with osteosarcoma, and 15 normal tissues. RSK2 gene expression levels in 30 specimens with osteosarcoma were significantly higher than those of normal tissues. We performed RNA interference on three OCLs to evaluate cell apoptosis, cell growth, cell proliferation, cell motility, chemosensitivity and oncogenicity. After transfection with RSK2 shRNA, increased cell apoptosis, cell growth inhibition, cell cycle progression, weaker cell proliferation, cell migration and weaker tumor formation were observed in all OCLs. These results suggested that RSK2 expression may mediate the biological activities of OS cells and RSK2 may be an effective therapeutic target for the treatment of osteosarcomas. The AKT/mTOR, MAPK/ERK/c-Fos and Bcl2/Bax pathways were analysed to clarify the mechanisms involved. SN - 1791-2423 UR - https://www.unboundmedicine.com/medline/citation/27082640/Downregulation_of_RSK2_influences_the_biological_activities_of_human_osteosarcoma_cells_through_inactivating_AKT/mTOR_signaling_pathways_ L2 - http://www.spandidos-publications.com/ijo/48/6/2508 DB - PRIME DP - Unbound Medicine ER -